Inflammatory Markers and Type 2 Diabetes as Prognostic Factors in Low-Risk Bladder Cancer

What is it about?

The study aimed to investigate the prognostic role of inflammatory markers and type 2 diabetes mellitus (T2DM) in predicting disease recurrence and progression in patients with low-risk non-muscle-invasive bladder cancer (NMIBC) enrolled in the Bladder Cancer Italian Active Surveillance Register (BIAS). The analysis included data from 214 patients enrolled in the BIAS project between January 2014 and December 2020. Inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelets-to-lymphocyte ratio (PLR), as well as T2DM, were found to be predictive of worse oncological and pathological outcomes in patients with high-risk NMIBC and muscle-invasive bladder cancer (MIBC) after radical cystectomy. However, their utility in patients with low-risk NMIBC is not known. The study found no association between NLR, LMR, and PLR with either disease recurrence or progression, and also no association was found for T2DM. These findings suggest that low-and high-risk bladder cancer may be driven by different pathophysiological mechanisms. Further evaluation and other prognostic factors are needed to better characterize the risk of disease recurrence and progression for low-risk NMIBC.

Featured Image

Why is it important?

This research is important because it investigates the utility of inflammatory markers and Type 2 diabetes mellitus (T2DM) as prognostic factors in predicting disease recurrence and progression in patients with low-risk non-muscle-invasive bladder cancer (NMIBC) who are undergoing active surveillance. This is crucial because even though several prognostic models based on clinical and pathological characteristics have been developed to aid in clinical decision-making and improve personalized care of patients with bladder cancer, their accuracy in predicting disease recurrence and progression remains low. Therefore, identifying new prognostic factors that can accurately predict disease recurrence and progression in patients with low-risk NMIBC is essential for improving patient outcomes. Key Takeaways: 1. The study found no association between inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelets-to-lymphocyte ratio (PLR)) and T2DM with the risk of disease recurrence and progression in patients with low-risk NMIBC undergoing active surveillance. 2. The study highlights the need for further evaluation and other prognostic factors to better characterize the risk of disease recurrence and progression for low-risk NMIBC. 3. The research emphasizes the importance of personalized care for patients with bladder cancer and the need for accurate prognostic models to improve patient outcomes.